MEDTR.E — Meditera Tibbi Malzeme Sanayi ve Ticaret AS Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareSpeculativeSmall CapNeutral

Market Cap
TRY3.23bn
Enterprise Value
TRY2.90bn
Revenue
TRY2.87bn

Annual cashflow statement for Meditera Tibbi Malzeme Sanayi ve Ticaret AS, fiscal year end - December 31st, TRY millions except per share, conversion factor applied.

	2021 December 31st	R2022 December 31st	R2023 December 31st	R2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	ARS
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	168	114	37.4	92	-11.7
Depreciation
Non-Cash Items	-113	65.5	636	557	129
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-29.8	-565	120	-558	-275
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	36.6	-335	869	206	19
Capital Expenditures	-9.23	-92	-300	-264	-192
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	2.9	11.4	417	472	363
Sale of Fixed Assets
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-6.33	-80.6	117	209	172
Financing Cash Flow Items	3.72	-11.8	-222	-269	-190
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	175	-130	-521	-302	-270
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	205	-546	465	112	-79.7